Vanguard Group Inc. Purchases 210,581 Shares of Xeris Biopharma Holdings, Inc. $XERS

Vanguard Group Inc. raised its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 2.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,109,644 shares of the company’s stock after buying an additional 210,581 shares during the period. Vanguard Group Inc. owned about 5.19% of Xeris Biopharma worth $44,522,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Millennium Management LLC lifted its stake in shares of Xeris Biopharma by 34.8% during the 4th quarter. Millennium Management LLC now owns 1,948,552 shares of the company’s stock worth $6,606,000 after acquiring an additional 502,853 shares during the last quarter. Nuveen Asset Management LLC increased its stake in Xeris Biopharma by 13.6% in the fourth quarter. Nuveen Asset Management LLC now owns 1,903,442 shares of the company’s stock worth $6,453,000 after purchasing an additional 228,380 shares during the period. D. E. Shaw & Co. Inc. lifted its position in shares of Xeris Biopharma by 38.4% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,363,452 shares of the company’s stock worth $4,622,000 after purchasing an additional 378,437 shares during the last quarter. Northern Trust Corp boosted its stake in shares of Xeris Biopharma by 3.3% during the fourth quarter. Northern Trust Corp now owns 1,196,381 shares of the company’s stock valued at $4,056,000 after purchasing an additional 38,155 shares during the period. Finally, Essex Investment Management Co. LLC grew its holdings in shares of Xeris Biopharma by 53.8% in the first quarter. Essex Investment Management Co. LLC now owns 730,444 shares of the company’s stock worth $4,010,000 after purchasing an additional 255,489 shares during the last quarter. 42.75% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. HC Wainwright assumed coverage on shares of Xeris Biopharma in a report on Tuesday, August 12th. They set a “buy” rating and a $10.00 price objective for the company. Wall Street Zen raised shares of Xeris Biopharma from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 9th. Oppenheimer boosted their price target on Xeris Biopharma from $6.00 to $7.00 and gave the company an “outperform” rating in a report on Friday, May 9th. Finally, Leerink Partners increased their price objective on Xeris Biopharma from $7.00 to $9.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 19th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $7.08.

Insider Buying and Selling at Xeris Biopharma

In other news, Director Dawn Halkuff sold 42,500 shares of Xeris Biopharma stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $7.28, for a total value of $309,400.00. Following the transaction, the director directly owned 115,000 shares in the company, valued at approximately $837,200. This trade represents a 26.98% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Kevin Mcculloch purchased 25,000 shares of Xeris Biopharma stock in a transaction dated Friday, June 13th. The stock was bought at an average cost of $4.38 per share, with a total value of $109,500.00. Following the completion of the transaction, the insider owned 1,708,585 shares in the company, valued at approximately $7,483,602.30. This represents a 1.48% increase in their position. The disclosure for this purchase can be found here. Insiders own 4.56% of the company’s stock.

Xeris Biopharma Stock Performance

NASDAQ XERS opened at $7.77 on Tuesday. The company has a market capitalization of $1.25 billion, a price-to-earnings ratio of -37.00 and a beta of 0.65. The company’s 50-day simple moving average is $5.60 and its two-hundred day simple moving average is $4.89. Xeris Biopharma Holdings, Inc. has a one year low of $2.48 and a one year high of $7.96.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.02. The business had revenue of $67.71 million during the quarter, compared to analysts’ expectations of $64.58 million. Equities analysts expect that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current fiscal year.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.